$ Value
$60K
Shares
120
Price
$497
Filed
Feb 5
Insider
Name
HAZEN SAMUEL N
Title
CEO
CIK
0001216838
Roles
Transaction Details
Transaction Date
2026-02-03
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
32,276
Footnotes
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.49 to $503.485, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.485 to $502.455, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.44 to $501.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $499.47 to $500.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.41 to $499.395, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.49 to $498.385, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.10 to $497.38, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | Pursuant to a power of substitution, on February 4, 2026, the Reporting Person transferred 1,045 shares of common stock of the Issuer to a trust in exchange for assets of equal value. The transfer was made at a price per share equal to $498.35 (the average of the high and low prices of shares of common stock of the Issuer on February 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the Reporting Person may be deemed to have beneficial ownership. The Reporting Person believes that the transfer of shares to the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
Filing Info
HAZEN SAMUEL N's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-10 | HCA | A | $0 |
| 2026-02-10 | HCA | F | $10.7M |
| 2026-02-04 | HCA | J | $521K |
| 2026-02-04 | HCA | J | $521K |
| 2026-02-03 | HCA | ▼ | $7.4M |
| 2026-02-03 | HCA | ▼ | $2.5M |
| 2026-02-03 | HCA | ▼ | $3.7M |
| 2026-02-03 | HCA | ▼ | $3.1M |
| 2026-02-03 | HCA | ▼ | $2.6M |
| 2026-02-03 | HCA | ▼ | $2.1M |
Other Insiders at HCA (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| FRIST THOMAS F JR | — | — | 2026-02-06 |
|
HAZEN SAMUEL N
CEO
|
— | $21.4M | 2026-02-10 |
| FRIST THOMAS F III | — | — | 2026-02-06 |
| HERCULES HOLDING II | — | — | 2026-02-06 |
| Frisco Holding II | — | — | 2026-02-06 |
| Elcan Patricia F | — | — | 2026-02-06 |
| Frist William R | — | — | 2026-02-06 |
|
Foster Jon M
EVP and COO
|
— | — | 2026-02-10 |
|
Cuffe Michael S.
EVP and Chief Clinical Officer
|
— | $747K | 2026-02-10 |
|
Wyatt Christopher F.
SVP & Controller
|
— | $2.0M | 2026-02-11 |
|
Berres Jennifer
SVP & Chief Human Res. Officer
|
— | $4.1M | 2026-02-11 |
|
McAlevey Michael R
EVP & Chief Legal & Admin Off.
|
— | $904K | 2026-02-18 |
|
Marks Mike A
EVP and CFO
|
— | — | 2026-02-10 |
|
Rossitto Erica
SVP & Chief Nurse Executive
|
— | — | 2026-02-10 |